Optimizing Bispecific Antibody Therapy in Relapsed-Refractory Multiple Myeloma: Real-World Evidence and Implementation Strategies

An expert explains that real-world data affirm the strong efficacy and manageable safety of bispecific antibodies like teclistamab in relapsed/refractory multiple myeloma—including in patients beyond trial eligibility—and that combining agents such as teclistamab and talquetamab offers promising options for high-risk cases; optimizing safety through step-up dosing, infection prophylaxis, and supportive care enables broader outpatient use, while ongoing research aims to expand their role earlier in treatment and explore stopping strategies after sustained minimal residual disease negativity to personalize and improve long-term patient outcomes.